High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.

doi:10.1200/PO.23.00348

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.

JCO precision oncology - 1 Mar 2024

Pfarr Nicole, von Schwarzenberg Karin, Zocholl Dario, Merkelbach-Bruse Sabine, Siemanowski Janna, Mayr Eva-Maria, Herold Sylvia, Kleo Karsten, Heukamp Lukas C, Willing Eva-Maria, Menzel Michael, Lehmann Ulrich, Bartels Stephan, Chakraborty Shounak, Baretton Gustavo, Demes Melanie C, Döring Claudia, Kazdal Daniel, Budczies Jan, Rad Roland, Wild Peter, Christinat Yann, McKee Thomas, Schirmacher Peter, Horst David, Büttner Reinhard, Stenzinger Albrecht, Sehouli Jalid, Vollbrecht Claudia, Hummel Michael, Braicu Elena I, Weichert Wilko

Abstract excerpt

PURPOSE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for patients with homologous recombination deficiency (HRD). The test that is most often used for the detection of HRD in clinical studies is the Myriad myChoice assay. However, other assays can also be used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Cancer Genomics and Diagnostics

Share to Genomic Instability

Share to Homologous Recombination

Share to Mutation

Share to Ovarian Neoplasms

Share to PARP inhibition in cancer therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 38513168
DOI: 10.1200/PO.23.00348
PMCID: PMC10965219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.PMID 38513168Read ↗

In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot studySemantic proximity Read ↗

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer DiagnosisSemantic proximity Read ↗

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian CarcinomaSemantic proximity Read ↗

Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.Semantic proximity Read ↗

Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.Semantic proximity Read ↗

Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.Semantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assaySemantic proximity Read ↗

Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization ProjectSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World CohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.